NasdaqGS - Nasdaq Real Time Price USD

Dynavax Technologies Corporation (DVAX)

11.21 +0.04 (+0.36%)
At close: April 26 at 4:00 PM EDT
11.00 -0.21 (-1.87%)
After hours: April 26 at 6:36 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
232,284.00
232,284.00
722,683.00
439,442.00
46,551.00
Cost of Revenue
50,167.00
50,167.00
262,153.00
173,572.00
13,910.00
Gross Profit
182,117.00
182,117.00
460,530.00
265,870.00
32,641.00
Operating Expense
207,832.00
207,832.00
178,008.00
132,384.00
107,863.00
Operating Income
-25,715.00
-25,715.00
282,522.00
133,486.00
-75,222.00
Net Non Operating Interest Income Expense
25,236.00
25,236.00
1,180.00
-11,036.00
-17,802.00
Other Income Expense
-3,888.00
-3,888.00
10,597.00
-44,929.00
17,784.00
Pretax Income
-4,367.00
-4,367.00
294,299.00
77,521.00
-75,240.00
Tax Provision
2,022.00
2,022.00
1,143.00
808.00
--
Net Income Common Stockholders
-6,389.00
-6,389.00
292,873.00
72,144.00
-75,240.00
Average Dilution Earnings
--
--
3,526.00
3,547.00
-4,124.00
Diluted NI Available to Com Stockholders
-6,389.00
-6,389.00
296,399.00
75,691.00
-79,364.00
Basic EPS
0.48
-0.05
2.32
0.62
-0.75
Diluted EPS
0.41
-0.05
1.97
0.57
-0.78
Basic Average Shares
128,286.50
128,733.00
126,398.00
116,264.00
100,753.00
Diluted Average Shares
134,358.50
128,733.00
150,797.00
133,006.00
101,504.00
Total Operating Income as Reported
-37,028.00
-37,028.00
283,522.00
134,486.00
-68,371.00
Rent Expense Supplemental
--
--
--
--
11,425.00
Total Expenses
257,999.00
257,999.00
440,161.00
305,956.00
121,773.00
Net Income from Continuing & Discontinued Operation
-6,389.00
-6,389.00
293,156.00
76,713.00
-75,240.00
Normalized Income
2,548.27
2,548.27
290,366.20
129,763.14
-86,215.00
Interest Income
31,993.00
31,993.00
7,912.00
140.00
1,260.00
Interest Expense
6,757.00
6,757.00
6,732.00
11,176.00
19,062.00
Net Interest Income
25,236.00
25,236.00
1,180.00
-11,036.00
-17,802.00
EBIT
2,390.00
2,390.00
301,031.00
88,697.00
-56,178.00
EBITDA
9,666.00
9,666.00
307,699.00
95,755.00
-46,843.00
Reconciled Cost of Revenue
50,167.00
50,167.00
262,153.00
173,572.00
13,910.00
Reconciled Depreciation
7,276.00
7,276.00
6,668.00
7,058.00
9,335.00
Net Income from Continuing Operation Net Minority Interest
-6,389.00
-6,389.00
293,156.00
76,713.00
-75,240.00
Total Unusual Items Excluding Goodwill
-11,313.00
-11,313.00
2,801.00
-53,586.00
10,975.00
Total Unusual Items
-11,313.00
-11,313.00
2,801.00
-53,586.00
10,975.00
Normalized EBITDA
20,979.00
20,979.00
304,898.00
149,341.00
-57,818.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-2,375.73
-2,375.73
11.20
-535.86
--
12/31/2020 - 2/19/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EOLS Evolus, Inc.
11.43
-0.26%
 
DCPH Deciphera Pharmaceuticals, Inc.
14.65
+3.31%
 
ESPR Esperion Therapeutics, Inc.
1.9000
-4.52%
 
AVDL Avadel Pharmaceuticals plc
17.81
-0.06%
 
ELAN Elanco Animal Health Incorporated
13.26
+1.69%
 
AQST Aquestive Therapeutics, Inc.
4.0700
+3.56%
 
NBIX Neurocrine Biosciences, Inc.
135.99
-1.28%
 
VTRS Viatris Inc.
11.57
+0.87%
 
IRWD Ironwood Pharmaceuticals, Inc.
7.82
-3.22%
 
TEVA Teva Pharmaceutical Industries Limited
13.81
+4.23%